Own-developed non-urology products divested or out-licensed:
Based on Photocure Technology®, the company developed and commercialized Metvix, a product for non-melanoma skin cancer and actinic keratosis. The product was divested to Galderma S.A. in 2009. To read more about the product, see the webpage: https://www.galderma.com/our-brands#expand-8
Photocure developed a cosmetic product to improve the overall appearance of skin, visibly reduce the outward signs of aging and minimize the appearance of pores. The product was sold to Bellus Medical (now Crown Aesthetics) in 2017. Please find more information about the product: https://crownaesthetics.com/products/allumera/
Photocure developed Cevira®, a photodynamic drug-device combination product in development for non-surgical treatment of high-grade cervical dysplasia. The product was out-licensed to Asieris Meditech Co., Ltd for development and commercialization in 2019.